Comparison of the Eight Different Treatment Regimens for the Hospitalized Patients with COVID-19: A Retrospective Cohort Study

authors:

avatar Mohammad Haji Aghajani 1 , avatar Elham Porheidar 2 , avatar Omid Moradi 3 , avatar asma Pourhosseingoli 1 , avatar Nilofar Taherpour 4 , avatar Armineh Barootkoob 3 , avatar Rezvan Hassanpour 3 , avatar Elmira Agah 5 , 6 , 7 , avatar seyed vahid mosavi 8 , 9 , avatar Mohammad Sistanizad ORCID 3 , 4 , *

Prevention of Cardiovascular Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Prevention of Cardiovascular Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Students’ Scientific Research Center, Tehran University of Medical Sciences,Tehran, Iran.
Neuroimmunology Research Association (NIRA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
Students’ Scientific Research Center, Tehran University of Medical Sciences,Tehran, Iran
Neuroimmunology Research Association (NIRA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Journal of Cellular & Molecular Anesthesia: Vol.6, issue 4; e151632
published online: August 07, 2021
article type: Research Article
DOI: https://doi.org/10.5812/jcma-151632

how to cite: Haji Aghajani M, Porheidar E, Moradi O, Pourhosseingoli A, Taherpour N, et al. Comparison of the Eight Different Treatment Regimens for the Hospitalized Patients with COVID-19: A Retrospective Cohort Study. J Cell Mol Anesth. 2021;6(4):e151632. https://doi.org/10.5812/jcma-151632.

Abstract

Background: Coronavirus disease 2019 (COVID -19) characterized by a mild to severe respiratory illness, has been affecting the world since late 2019 and leading to an increase in hospitalizations and deaths. There is still no specific highly effective treatment for this disease. This study aimed to compare the efficacy of the eight different treatment regimens for the hospitalized patients with COVID-19.
Methods: This retrospective cohort study was conducted on the hospitalized patients who had laboratory-confirmed COVID-19 by a real-time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) of nasopharyngeal samples.
Results: Among all patients hospitalized with COVID-19 between March to September 2020, 861 patients were included in the study. This study indicated that treatment protocols included either remdesivir or favipiravir were superior to hydroxychloroquine in reducing the risk of in-hospital mortality of the patients with confirmed COVID-19, especially in critical patients defined as those who were ICU admitted or under mechanical ventilation (HR, 0.43; 95% CI, 0.23 to 0.82; P=0.011 and HR, 0.45; 95% CI, 0.22 to 0.90; P=0.024, respectively). Whereas receiving lopinavir/ritonavir in combination with either hydroxychloroquine plus interferon β and corticosteroids (HR, 1.85; 95% CI, 1.17 to 2.94; P=0.009), hydroxychloroquine plus interferon β (HR, 1.66; 95% CI, 1.01 to 2.74; P=0.046), or interferon β (HR, 1.80; 95% CI, 1.12 to 2.89; P=0.015) was associated with a significant increase in this risk.
Conclusion: Our findings indicate that using remdesivir and favipiravir in combination with interferon β and corticosteroids might be beneficial in hospitalized patients with COVID-19, especially in the critical ones.

References

  • 1.

    References are in the PDF file of the article.